Quantcast

Latest Mirtazapine Stories

2013-10-08 10:09:58

For more than a decade the research group of Brown University Professor Walter Atwood has doggedly pursued the workings of the JC polyomavirus, which causes a disease called PML that fatally degrades the central nervous system of patients with weakened immune systems. In a study published online Oct. 2 in the Journal of Virology, his team describes how it gains entry into cells: It breaks in via certain receptors of the neurotransmitter serotonin called 5-HT2 receptors. Atwood, lead author...

4809a5a530001ec159a1b0d285aed72d
2011-08-04 06:45:00

Antidepressant use and the risk of adverse outcomes in older people: population-based cohort study New generation antidepressants, known as selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of several severe adverse outcomes in older people compared with older tricyclic antidepressants (TCAs), finds a study published in the British Medical Journal on August 3. The authors say the risks and benefits of different antidepressants should be carefully evaluated...

2009-11-24 17:24:48

However, bupropion XL and mirtazapine can benefit people suffering from depression There is no scientific proof that people suffering from depression can benefit from taking reboxetine. However, clinical trials do provide proof of benefit of bupropion XL and mirtazapine: both agents can alleviate symptoms. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 24 November 2009. The final evaluation of reboxetine and...

2009-07-09 15:07:00

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for REMERON(R) /Reflex(R) (mirtazapine)15 mg Tablets for the treatment of major depressive disorder.(1) The product was developed jointly with Meiji Seika Kabushiki Kaisha, Ltd. Schering-Plough and Meiji Seika will market the product under the trade names, REMERON(R) and Reflex(R),...

b15f66812eec8fbb658e618e6d9b96da1
2009-01-29 11:35:00

Researchers have concluded that Pfizer Inc's Zoloft and Forrest Laboratories Inc's Lexapro are superior antidepressant drugs compared to 12 other new drugs in their class. Doctors previously considered there to be very little difference between various antidepressants due to previous research, including one 2006 US government study that concluded that patients with major depression fared equally as well on various antidepressant drugs. However, after analyzing data from 117 studies...

2008-07-20 03:00:15

By Raymond, Colette B Wazny, Lori D; Honcharik, Patricia L Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin reuptake inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine. Although very little research has been conducted on the use of antidepressants in CKD, health care providers should be aware of renal dose adjustments for these agents, drug...

2006-07-03 10:21:35

NEW YORK (Reuters Health) - Two prior unsuccessful antidepressant trials usually spell treatment failure with a third, new research suggests. In this scenario, remission rates are less than 20 percent. The findings of the study, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, "continue to be sobering," AJP editor-in-chief Dr. Robert Freedman said in a statement. "By the third wave of the study, the rate of remission continues to be quite low, which...

2006-06-28 16:43:24

Corrects paragraph four to show that Cypress and Forest Laboratories Inc. are developing a separate drug called milnacipran for the treatment of fibromyalgia. Makes clear that mirtazapine and milnacipran are different drugs. BOSTON (Reuters) - Cypress Bioscience Inc. said on Tuesday it is dropping development of its experimental drug to treat sleep apnea after it failed to prove effective in a clinical trial. Cypress and Organon, a unit of Akzo Nobel, had each independently...

2006-06-28 16:36:56

BOSTON (Reuters) - Cypress Bioscience Inc. said on Tuesday it is dropping development of its experimental drug to treat sleep apnea after it failed to prove effective in a clinical trial. Cypress and Organon, a unit of Akzo Nobel, had each independently conducted mid-stage, or Phase II, trials evaluating combinations of the drug, mirtazapine, with another approved drug. Sleep apnea is a common breathing disorder which affects 15 to 20 million people in the United States and is...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related